SM 31900

structure in first source

Also Known As:

(3S)-7-chloro-3-(2-((1R)-1-carboxyethoxy)-4-aminomethylphenyl)aminocarbonylmethyl-1,3,4,5-tetrahydrobenz(c,d)indole-2-carboxylic acid hydrochloride; SM-31900

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - SM 31900: 3

Experts

1.	Tanaka, Hiroyasu: 2 articles (01/2006 - 04/2003)
2.	Aoki, Yoko: 1 article (07/2007)
3.	Kinouchi, Hiroyuki: 1 article (07/2007)
4.	Kojima, Kanako: 1 article (07/2007)
5.	Kure, Shigeo: 1 article (07/2007)
6.	Matsubara, Yoichi: 1 article (07/2007)
7.	Mizoi, Kazuo: 1 article (07/2007)
8.	Narisawa, Ayumi: 1 article (07/2007)
9.	Oda, Masaya: 1 article (07/2007)
10.	Omae, Tomoya: 1 article (07/2007)

Related Diseases

1.	Stroke (Strokes) 01/01/2006 - "In fact, SM-18400 and SM-31900 exhibited efficacy in several animal stroke models using intravenous infusion protocols. " 04/01/2003 - "These studies revealed that SM-31900 can exert a neuroprotective effect when it is administered up to at least 60min after the onset of ischemia in the MCAo model, an animal model of stroke, indicating that SM-31900 is a good candidate for treating acute brain ischemia."
2.	Ischemia 04/01/2003 - "These studies revealed that SM-31900 can exert a neuroprotective effect when it is administered up to at least 60min after the onset of ischemia in the MCAo model, an animal model of stroke, indicating that SM-31900 is a good candidate for treating acute brain ischemia."
3.	Brain Ischemia (Cerebral Ischemia) 04/01/2003 - "These studies revealed that SM-31900 can exert a neuroprotective effect when it is administered up to at least 60min after the onset of ischemia in the MCAo model, an animal model of stroke, indicating that SM-31900 is a good candidate for treating acute brain ischemia."
4.	Infarction (Infarctions) 04/01/2003 - "In experiment I, SM-31900 significantly reduced the infarct volume by 37% at a dosage of 0.38mg/kg bolus followed by 1.5mg/kg/h continuous infusion (0.38mg/kg+1.5mg/kg/h). " 04/01/2003 - "In experiment II, the neuroprotective effect of SM-31900 was also significant, with a 25% reduction in infarct volume at a dosage of 0.38mg/kg+1.5mg/kg/h, and a 40% reduction at 1.5mg/kg+6.0mg/kg/h. " 04/01/2003 - "SM-31900, a novel NMDA receptor glycine-binding site antagonist, reduces infarct volume induced by permanent middle cerebral artery occlusion in spontaneously hypertensive rats." 07/01/2007 - "An antagonist for the NMDA glycine site, SM-31900, attenuated infarct size, suggesting that glycine operated via the NMDA receptor. "
5.	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 04/01/2003 - "SM-31900, a novel NMDA receptor glycine-binding site antagonist, reduces infarct volume induced by permanent middle cerebral artery occlusion in spontaneously hypertensive rats."

Related Drugs and Biologics

1.	Neuroprotective Agents
2.	N-Methyl-D-Aspartate Receptors (NMDA Receptors)
3.	Glycine (Aminoacetic Acid)
4.	N-Methylaspartate (NMDA)
5.	SM 18400

Related Therapies and Procedures

1.	Intravenous Infusions